Scientific discovery dossier · Experimental discoveries

RAS(ON) tri-complex pharmacology — preclinical discovery basis

Preclinical pharmacology of RAS(ON) multi-selective tri-complex inhibitors (literature basis for clinical RAS(ON) programs)

Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.

Scope / models: Pancreas, Multiple / solid tumors — Hücre / hayvan modelleri
Molecular mechanism: Tri-complex inhibitor class binding active (GTP-bound) RAS; mutation-selective and multi-selective variants moved into clinical programs.
Experimental models: Cell lines and animal models (clinical translation is on separate cards).
Translational distance: Human clinical benefit cannot be inferred here. Clinical: RMC-6236-001, RASolute 302, elironrasib/daraxonrasib.
Research biomarker: RAS(ON)

For patients

What is being studied? Lab studies help explain how drugs try to switch off RAS in cancer. They are not a treatment promise yet.

Why promising? Pharmacology class that underpins clinical RAS(ON) programs (e.g., RMC-6236 / RASolute 302).

What is not proven? Human clinical benefit cannot be inferred from this card; see clinical cards.

Is this standard care today? No — this is a laboratory/scientific discovery dossier, not a treatment option.

Preclinical discovery card — no fabricated DOI. Clinical translation: NCT05379985, NCT06625320, NCT06128551.

Limitations: Preklinik → klinik atlama yok; primer farmakoloji DOI hekim kaynak listesine eklenecek.